Global Oral Antidiabetic Drugs Market Growth, Share, Size, Trends and Forecast (2022 - 2028)
Segmented by Drug Class Analysis;
Sulfonylureas - Glimepiride, Gliclazide, Glyburide and Others, Meglitinides - Repaglinide and Nateglinide, Biguanides - Metformin and Others, Alpha-glucosidase inhibitors - Acarbose, Voglibose and Others.Segmented by Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2018 - 2028).Introduction
Global Oral Antidiabetic Drugs Market (USD Million), 2018 - 2028
# | Global |
---|---|
2018 | 107.1 |
2019 | 119.8 |
2020 | 123.7 |
2021 | 143.0 |
2022 | 160.8 |
2023 | 163.4 |
2024 | 168.7 |
2025 | 171.2 |
2026 | 200.3 |
2027 | 216.5 |
2028 | 230.2 |
In the year 2021, the Global Oral Antidiabetic Drugs Market was valued at USD 23,402.57 million. The size of this market is expected to increase to USD 31,529.04 million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of 4.4%.
Global Oral Antidiabetic Drugs Market Report Snapshot
Parameters | Description |
---|---|
Market | Global Oral Antidiabetic Drugs Market |
Study Period | 2018 - 2028 |
Base Year (for Oral Antidiabetic Drugs Market Size Estimates) | 2021 |
Study Scope |
|
Market Segmentation |
|
Geographical Coverage |
|
Company Coverage |
|
Premium Insights |
|
Market Analysis
This report extensively covers different segments of Global Oral Antidiabetic Drugs Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).
Global Oral Antidiabetic Drugs Market Analysis
In this report, the Global Oral Antidiabetic Drugs Market has been segmented by Drug Class Analysis and Geography. Indian diabetes market into three segments - Oral Anti-diabetics, Insulin and Diabetes Diagnostics. For each of the aforementioned categories, the report provides historical and future market sales, performance of key classes and the performance of top players. The research study serves as an exceptional tool to understand the Diabetes pharmaceutical market epidemiology. The total emerging markets Severe Hypoglycemia market size and market size by therapies in Japan is also mentioned. Severe Hypoglycemia Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the Severe Hypoglycemia market or expected to get launched in the market during the study period. Europe is expected to hold the second largest share of the global SGLT2 inhibitors market driven by growing industry and stringent manufacturing rules and regulations. The SGLT2 inhibitors market in Asia Pacific is projected to witness a promising growth in the near future led by emerging markets such as India and China. The market in the region is expected to grow at higher rate owing to rising prevalence of diabetes and well-established health care infrastructure. Europe is expected to hold the second largest share of the global SGLT2 inhibitors market driven by growing industry and stringent manufacturing rules and regulations.
Global Oral Antidiabetic Drugs Market, Segmentation by Drug Class Analysis
The Global Oral Antidiabetic Drugs Market has been segmented by Drug Class Analysis into Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors. The complete Global Oral Antidiabetic Drugs Market segmentation by Drug Class Analysis can be seen below:
- Global Oral Antidiabetic Drugs Market,By Drug Class Analysis
- Sulfonylureas
- Glimepiride
- Gliclazide
- Glyburide
- Others
- Meglitinides
- Repaglinide
- Nateglinide
- Biguanides
- Metformin
- Others
- Alpha-glucosidase inhibitors
- Acarbose
- Voglibose
- Others
- Sulfonylureas
This report provides market size in USD Million and Year on Year (YOY) growth analysis for all the Drug Class Analysiss mentioned above for historic (2018 - 2021) and forecast (2022 - 2028) periods with 2021 considered as the base year.
The report also provides an analysis of why the market size of the various segments by Drug Class Analysis is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Global Oral Antidiabetic Drugs Market, by Drug Class Analysis (USD Million), 2018 - 2028
# | Sulfonylureas | Meglitinides | Biguanides | Alpha-glucosidase inhibitors |
---|---|---|---|---|
2018 | 56.4 | 78.6 | 66.4 | 102.5 |
2019 | 67.1 | 92.8 | 68.3 | 119.4 |
2020 | 67.4 | 97.7 | 69.1 | 135.1 |
2021 | 69.7 | 103.8 | 69.1 | 140.4 |
2022 | 73.7 | 113.2 | 82.7 | 166.4 |
2023 | 85.3 | 115.2 | 90.7 | 177.2 |
2024 | 94.9 | 121.3 | 92.9 | 190.3 |
2025 | 98.3 | 134.4 | 94.9 | 226.5 |
2026 | 112.1 | 142.8 | 98.4 | 252.7 |
2027 | 120.9 | 163.8 | 112.8 | 303.1 |
2028 | 126.2 | 177.7 | 127.4 | 326.7 |
Global Oral Antidiabetic Drugs Market, Segmentation by Geography
In this report, the Global Oral Antidiabetic Drugs Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Oral Antidiabetic Drugs Market Share (%), by Geographical Region, 2021
North America | Europe | Asia Pacific | Middle East & Africa | Latin America |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
Find below the list of Countries covered in each of the aforementioned geographical regions:
North America - United States, Canada and Mexico
Latin America - Brazil, Argentina and Rest of Latin America
Europe - Germany, United Kingdom, France, Italy, Spain and Rest of Europe
Asia Pacific - Japan, China, India, Australia & New Zealand, South Korea, ASEAN (Association of South East Asian Nations) and Rest of Asia Pacific
Middle East & Africa - GCC Countries, Egypt, Israel, South Africa, Rest of Middle East & Africa
This report provides market size in USD Million and Year on Year (YOY) percentage growth analysis for the Oral Antidiabetic Drugs Market in all the Regions and Countries (specified above) for historic (2018 - 2021) and forecast (2022 - 2028) Periods with 2021 considered as the base year.
This report also provides an analysis of why the market size of Oral Antidiabetic Drugs in various regions and countries is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Market Dynamics
This report provides an in depth analysis of various factors that impact the dynamics of Global Oral Antidiabetic Drugs Market. These factors include; Market Drivers, Restraints and Opportunities Analysis, Market Opportunity Mapping, PEST (Political, Economic, Social and Technological) Analysis and Porter's Five Forces Analysis.
Drivers, Restraints and Opportunity Analysis
- The growth of the Global Oral Antidiabetic Drugs Market is driven by; Global Oral Anti-Diabetic Market Drivers: Impact Analysis, Rising Prevalence Of Diabetes Mellitus and Increase In Obesity.
- While the growth of Global Oral Antidiabetic Drugs Market is currently hindered by; Global Oral Anti-Diabetic Market Restraints: Impact Analysis and High Cost of Drugs.
- Global Oral Antidiabetic Drugs Market has good growth potential in the future due to the new market opportunities that are being created. The opportunities in this market include; Market Strength.
- Global Oral Anti-Diabetic Market Drivers: Impact Analysis.
- Rising Prevalence Of Diabetes Mellitus.
- Increase In Obesity.
- Global Oral Anti-Diabetic Market Restraints: Impact Analysis.
- High Cost of Drugs.
- Market Strength.
Market Opportunity Map
This report provides market opportunity map for Oral Antidiabetic Drugs Market. The opportunity map (by market segments; Drug Class Analysis) is calculated based on current year market estimates, CAGR and collective revenue over the forecast period. Since, CAGR has been estimated considering all the factors impacting the market; starting from the company's presence, buyer behaviour, to government interference or support. The opportunity map inherently considers all the aforementioned factors impacting the market. The bubble size reflects the estimated opportunity for a particular segment or region, therefore, bigger the bubble size, larger the opportunity.
Global Oral Antidiabetic Drugs Market, Opportunity Map, By Region (2018 - 2028)
North America | Europe | Asia Pacific | Middle East & Africa | Latin America |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
PEST (Political, Economic, Social and Technological) Analysis
This report provides PEST analysis of Oral Antidiabetic Drugs Market. Various factors such as government interference in the market such as regulations (which include but are not limited to pricing and intellectual property policies) that might impact the market are analysed.
This report also provides an analysis of Economic factors affecting the market such as; purchasing power, which directly influences the market growth.
This report also provides an analysis of social factors such as social norms or cultural beliefs inhibiting or promoting the growth of the market
As part of PEST analysis, this report also provides analysis of the impact of Technological factors on growth or decline of a market.
- In depth analysis and insights about the impact of political factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of economic factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of social factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of technological factors on this market will be provided in the final report.
Porter's Five Force Analysis
This report provides Porter's Five Forces analysis of Global Oral Antidiabetic Drugs Market, which include; Bargaining Power of Suppliers, Bargaining Power of Buyers, Threat of New Entrants, Threat of Substitutes and Competitive Rivalry.
Bargaining Power of Suppliers:
Various factors such as; Supplier Switching Costs Relative to Firm Switching Costs, Supplier Competition and Possibility of Forward Integration, Presence of Substitute Inputs, Strength of Distribution Channels, and Supplier Concentration to Firm Concentration Ratio would be analysed to estimate bargaining power of suppliers in the Global Oral Antidiabetic Drugs Market. Bargaining power of suppliers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Bargaining Power of Suppliers
Supplier Switching Costs Relative To Firm Switching Costs | Strength of Distribution Channels | Supplier Concentration to firm Concentration Ratio | Presence of Substitute Inputs | Supplier Competition and Possibly of Forward Integration |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
Bargaining Power of Buyers:
Various factors such as; Buyer Concentration to Firm Concentration Ratio, Buyer Switching Costs, Availability of Existing Substitute Products, Buyer Price Sensitivity, and Degree of Dependency upon Existing Channels of Distribution would be analysed to estimate bargaining power of buyers in the Global Oral Antidiabetic Drugs Market. Bargaining power of buyers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Bargaining Power of Buyers
Buyer Competition to Firm Concentration Ratio | Buyer Switching Costs | Availability of existing Substitute Products | Buyer Price Sensitivity | Degree of Dependency upon Existing Channels of Distribution |
---|---|---|---|---|
10 | 15 | 25 | 45 | 32 |
Threat of Substitutes:
Various factors such as; Availability of Substitutes, Number of Available Substitutes, Price of Substitute Products, Buyer Switching Costs, and Buyer Propensity to Substitute would be analysed to estimate threat of substitutes in the Global Oral Antidiabetic Drugs Market. Threat of substitutes will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Threat of Substitutes:
Availability of Substitutes | Number of Available Substitutes | Price of Substitute Products | Buyer Switching Costs | Buyer Propensity to Substitute |
---|---|---|---|---|
20 | 35 | 10 | 2 | 5 |
Threat of New Entrants:
Various factors such as; Barriers to Entry, Economies of Scale, Product Differentiation, Customer Loyalty, Network Effect, and Access to Distribution Channels would be analysed to estimate threat of new entrants in the Global Oral Antidiabetic Drugs Market. Threat of new entrants will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Threat of New Entrants:
Barriers to entry | Economics of scale | Product Differentiation | Customer Loyalty | Network Effect | Access to Ditribution Channels |
---|---|---|---|---|---|
2 | 35 | 25 | 10 | 15 | 55 |
Competitive Rivalry:
Various factors such as; Firm concentration Ratio, Level of Advertising Expense, Sustainable Competitive Advantage through Innovation, Competitive Strategy and Degree of Transparency would be analysed to estimate competitive rivalry in the Global Oral Antidiabetic Drugs Market. Competitive rivalry will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Industry Rivalry:
Firm Concentration Ratio | Level of Advertising Expense | Sustainable Competitive Adavantage through Innovation | Degree of Transparency | Competitive strategy |
---|---|---|---|---|
5 | 10 | 15 | 35 | 45 |
Competitive Landscape Analysis
Key players in Global Oral Antidiabetic Drugs Market include, Abbott Laboratories, Biocon, Ltd, Eli Lilly and Company, Sun Pharma Industries, Ltd, Novo Nordisk A/S, Pfizer, Sanofi and Novartis.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
Company SWOT Analysis
This report also provides Heat map analysis of Products/Services Offered by different companies operating in this market.
Competitors Products/Services Heat Map Analysis
Company Vs. Product/Service | Company 1 | Company 2 | Company 3 | Company 4 | Company 5 | Company 6 | Company 7 | Company 8 | Company 9 | Company 10 |
---|---|---|---|---|---|---|---|---|---|---|
Product 1/Service 1 | ||||||||||
Product 2/Service 2 | ||||||||||
Product 3/Service 3 | ||||||||||
Product 4/Service 4 | ||||||||||
Product 5/Service 5 | ||||||||||
Product 6/Service 6 | ||||||||||
Product 7/Service 7 | ||||||||||
Product 8/Service 8 |
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class Analysis
- Market Snapshot, By Region
- Market Opportunity Map
- Global Oral Antidiabetic Drugs Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Global Oral Anti-Diabetic Market Drivers: Impact Analysis
- Rising Prevalence Of Diabetes Mellitus
- Increase In Obesity
- Restraints
- Global Oral Anti-Diabetic Market Restraints: Impact Analysis
- High Cost of Drugs
- Opportunities
- Market Strength
- Drivers
- Regulatory Scenario
- Reimbursement Scenario
- Mergers & Acquisitions, Collaborations & Partnerships, Agreements
- Pipeline Analysis/Technological Advancements
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bragaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Industry Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Oral Antidiabetic Drugs Market,By Drug Class Analysis, 2020 - 2030 (USD Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Sulfonylureas
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Glimepiride
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Gliclazide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Glyburide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Glimepiride
- Meglitinides
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Repaglinide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Nateglinide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Repaglinide
- Biguanides
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Metformin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Metformin
- Alpha-glucosidase inhibitors
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Acarbose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Voglibose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Acarbose
- Sulfonylureas
- Global Oral Antidiabetic Drugs Market, By Geography, 2020 - 2030 (USD Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- United States
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Canada
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- United States
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Germany
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- United Kingdom
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- France
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Italy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Spain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Rest of Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Germany
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Japan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- China
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- India
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Australia & New Zealand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- South Korea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- ASEAN (Association of South East Asian Countries)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Rest of Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Japan
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Brazil
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Mexico
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Argentina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Rest of Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Brazil
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- GCC
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Israel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- South Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- Rest of Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Analysis, 2018 - 2028 (USD Million)
- GCC
- North America
- Global Oral Antidiabetic Drugs Market,By Drug Class Analysis, 2020 - 2030 (USD Million)
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Abbott Laboratories
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Biocon, Ltd
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Eli Lilly and Company
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Sun Pharma Industries, Ltd
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Novo Nordisk A/S
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Pfizer
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Sanofi
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Novartis
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Abbott Laboratories
- Analyst Views
- Future Outlook of the Market
ReAnIn's Most Viewed Titles:
In the year 2021, the Global Organ Preservation Solutions Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2021, the Global Orthodontics Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2021, the Global Oral Biologics Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2021, the Global Oral Proteins and Peptides Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%